Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial

de Boer, N.L., van Kooten, J.P., Burger, J.W.A., C. Verhoef (Kees), J.G.J.V. Aerts (Joachim) and Madsen, E.V.E.

2019

BMJ Open , Volume 9 - Issue 5

Additional Metadata
Persistent URL	doi.org/10.1136/bmjopen-2018-026779, hdl.handle.net/1765/117722
Journal	BMJ Open
Organisation	Department of Surgery
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	de Boer, N.L., van Kooten, J.P., Burger, J.W.A., Verhoef, K., Aerts, J., & Madsen, E.V.E. (2019). Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. BMJ Open, 9(5). doi:10.1136/bmjopen-2018-026779

Publication